RASAZIL, ALZIRAS, RASAGILINE MLABS, RASAGALINE B&B (Micro Labs Pty Ltd)
Product name
RASAZIL, ALZIRAS, RASAGILINE MLABS, RASAGALINE B&B
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
168 working days (255)
Active ingredients
Rasagiline (as mesilate)
Registration type
New generic medicine
Indication
RASAZIL, ALZIRAS, RASAGILINE MLABS, RASAGALINE B&B (tablets) is indicated for the symptomatic treatment of idiopathic Parkinson's disease (PD) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.